sur ONXEO (EPA:ALONX)
Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates
Valerio Therapeutics S.A. has announced its financial results for the first half of 2024. Key highlights include the acquisition of Emglev Therapeutics, aimed at advancing their single-domain antibodies (sdAbs) technology. The VIO-01 trial is progressing through Phase 1 dose escalation, exploring its potential as a new anti-cancer treatment.
The company reported no consolidated revenues for the period ending June 30, 2024. Operating expenses decreased to €10.8 million from €11.6 million in the first half of 2023. The net loss was €11 million, improved slightly from €11.6 million in the previous year.
Valerio's cash balance stood at €4 million as of June 30, 2024. The company is leveraging shareholder loans and Research Tax Credits to maintain financial visibility through the end of the year.
In addition to financial updates, Valerio continues to optimize its PlatON™ platform and develop VIO-01 through dose escalation in clinical trials. The company remains committed to creating value through its innovative oncology drug pipeline.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ONXEO